Kidney Inflammation Warning For PPI Omeprazole In Europe
Cases of acute tubulointerstitial nephritis linked to omeprazole use flagged to the EMA leads to new product information warnings related to a possible risk of kidney inflammation for drugs containing the PPI sold in the EU.
You may also be interested in...
Two Swedish companies are working on tackling GERD – one with a drug, one with a device.
FDA approves warning for severe cutaneous adverse reactions on labeling for Perrigo's 131 20-mg omeprazole delayed-release tablet products across unflavored and cool mint or wild berry-mint options and 14-, 28- and 42-count packages.
FDA approves request after Nexium 24HR marketer Haleon responded March to changes-being-effected letter asking for label change to the delayed-release PPI.